PD-L1 t-haNK cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for PD-L1 t-haNK cells, covering 2026-04-08 to 2026-04-08. Get the full timeline:
Most recent: Clinical Trial Update: Pembrolizumab + N-803 Alone or in Combination With PD-L1 t-haNK Cells for Resectable Head and Neck Squamous Cell Carcinoma [Phase 2]